ReviewInternational journal of molecular sciences2021
SMADS-Mediate Molecular Mechanisms in Sjögren's Syndrome.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Spatiotemporal orchestration of the salivary gland immune microenvironment in Sjögren's disease: a multidimensional framework of epithelial licensing, lymphoid neogenesis, and stromal remodeling.Frontiers in immunology · 2026Review
- Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF-β1/Smad Signaling Pathway.Mediators of inflammation · 2026Article
- Histone lactylation: a metabolic-epigenetic bridge linking glycolysis to salivary gland fibrosis in Sjögren's disease.Frontiers in immunology · 2026Review
- Macrophage polarization in Sjögren's syndrome: from mechanisms to therapeutic translation.Frontiers in immunology · 2026Review
- Review
- Knockdown of TBRG4 suppresses the migration, invasion, and epithelial-to-mesenchymal transition of pancreatic cancer cells via TGF-β/smad3 signaling.Histology and histopathology · 2025Article
- Current Insights on Salivary Gland Adenoid Cystic Carcinoma: Related Genes and Molecular Pathways.Genes · 2025Review
- The Function of the TGFβ Signaling Pathway in Connective Tissue Diseases: From Biology to Clinical Application.Journal of inflammation research · 2025Review
- G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.Acta pharmacologica Sinica · 2024Article
- Primary Sjögren's syndrome: new perspectives on salivary gland epithelial cells.European journal of medical research · 2024Review
- Duct ligation/de-ligation model: exploring mechanisms for salivary gland injury and regeneration.Frontiers in cell and developmental biology · 2024Review
- Current developments and opportunities of pluripotent stem cells-based therapies for salivary gland hypofunction.Frontiers in cell and developmental biology · 2024Review
- Towards a Unified Approach in Autoimmune Fibrotic Signalling Pathways.International journal of molecular sciences · 2023Review
- Analysis of MIR27A (rs11671784) Variant Association with Systemic Lupus Erythematous.Life (Basel, Switzerland) · 2023Article
- Mechanisms of Yajieshaba in the treatment of liver fibrosis through the Keap1-Nrf2 signaling pathway.Frontiers in pharmacology · 2023Article
- Research progress of stem cell therapy for endometrial injury.Materials today. Bio · 2022Review
- Sjögren's Syndrome-Related Organs Fibrosis: Hypotheses and Realities.Journal of clinical medicine · 2022Review
- TGF-β1/Smad Signalling in Proliferative Glomerulonephritis Associated with Autoimmune Diseases.Mediterranean journal of rheumatology · 2022Review
- E-Cadherin Signaling in Salivary Gland Development and Autoimmunity.Journal of clinical medicine · 2022Review
- Cadherin Signaling in Cancer and Autoimmune Diseases.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is considerable interest in delineating the molecular mechanisms of action of transforming growth factor-β (TGF-β), considered as central player in a plethora of human conditions, including cancer, fibrosis and autoimmune disease. TGF-β elicits its biological effects through membrane bound serine/threonine kinase receptors which transmit their signals via downstream signalling molecules, SMADs, which regulate the transcription of target genes in collaboration with various co-activators and co-repressors. Until now, therapeutic strategy for primary Sjögren's syndrome (pSS) has been focused on inflammation, but, recently, the involvement of TGF-β/SMADs signalling has been demonstrated in pSS salivary glands (SGs) as mediator of the epithelial-mesenchymal transition (EMT) activation. Although EMT seems to cause pSS SG fibrosis, TGF-β family members have ambiguous effects on the function of pSS SGs. Based on these premises, this review highlights recent advances in unravelling the molecular basis for the multi-faceted functions of TGF-β in pSS that are dictated by orchestrations of SMADs, and describe TGF-β/SMADs value as both disease markers and/or therapeutic target for pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.